Skip to main content
SpringerLink
Log in

Safety Pharmacology Evaluation of Biopharmaceuticals

  • Living reference work entry
  • First Online:
Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays

  • 73 Accesses

Abstract

Biotechnology-derived pharmaceuticals or biopharmaceuticals are molecules such as monoclonal antibodies, bispecific antibodies, soluble/decoy receptors, hormones, enzymes, cytokines, and growth factors that are used to diagnose, treat, or prevent various diseases. Safety pharmacology assessment of biopharmaceuticals has evolved since the approval of the first example (recombinant human insulin) in 1982. This evolution is ongoing and is informed by various International Harmonization Guidelines. Based on these guidelines, the potential undesirable effect of every drug candidate (small molecule or large molecule) on the cardiovascular, central nervous, and respiratory systems, referred to as the “Core Battery,” should be assessed prior to first-in-human administration. However, assessment of biopharmaceuticals poses unique challenges such as choice of test species and integration of relevant safety pharmacology parameters into repeat-dose toxicity studies. This chapter reviews the evolution of assessment of biopharmaceuticals using examples from approval packages of marketed agents and discusses the past, current, and new approaches and methods that can be used to generate high-quality data for the safety pharmacology assessment of biopharmaceuticals.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Similar content being viewed by others

References and Further Reading

  • Amouzadeh HR, Vargas HM (2013) Safety pharmacology assessment of biopharmaceuticals. In: Vogel HG et al (eds) Drug discovery and evaluation: safety and pharmacokinetic assays. Springer, Berlin Heidelberg, pp 555–560

    Chapter  Google Scholar 

  • Andersen NK, Meyer O, Bradley A, Dragsted N, Lassen AB, Sjögren I, ..., Milne A (2017) Evaluation of the PhysioTel™ Digital M11 cardiovascular telemetry implant in socially housed cynomolgus monkeys up to 16 weeks after surgery. J Pharmacol Toxicol Methods 87:82–92

    Google Scholar 

  • Authier S, Vargas HM, Curtis MJ et al (2013) Safety pharmacology investigations in toxicology studies: an industry survey. J Pharmacol Toxicol Meth 68:44–51

    Article  CAS  Google Scholar 

  • Berman CL, Cannon K, Cui Y et al (2014) Recommendations for safety pharmacology evaluations of oligonucleotide-based therapuetics. Nucleic Acid Ther (in review)

    Google Scholar 

  • Bhatt S, Northcott C, Wisialowski T, Li D, Steidl-Nichols J (2019) Preclinical to clinical translation of hemodynamic effects in cardiovascular safety pharmacology studies. Toxicol Sci 169(1):272–279

    Article  CAS  PubMed  Google Scholar 

  • Bonson K, Sun S (2011) FDA’s draft decision tree for assessment of abuse potential presented at the science of abuse liability assessment. Rockville: Legacy Hotel

    Google Scholar 

  • Bowes J, Brown AJ, Hamon J et al (2012) Reducing safety-related drug attrition: the use of in vitro pharmacological profiling. Nature Rev Drug Discov 11:909–922

    Article  CAS  Google Scholar 

  • Breitschaft A, Hu K, Darstein C, Ligueros-Saylan M, Jordaan P, Song D, Hudson M, Shah R (2013) Effects of subcutaneous pasireotide on cardiac repolarization in healthy volunteers: a single-center, phase I, randomized, four-way crossover study. J Clin Pharmacol. https://doi.org/10.1002/jcph.213

  • Brown DG, Wobst HJ (2021) A decade of FDA-approved drugs (2010–2019): trends and future directions. J Med Chem 64(5):2312–2338

    Article  CAS  PubMed  Google Scholar 

  • Bussiere JL (2008) Species selection considerations for preclinical toxicology studies for biotherapeutics. Expert Opin Drug Metab Toxicol 4:871–877

    Article  CAS  PubMed  Google Scholar 

  • Bussiere JL et al (2019) Nonclinical safety evaluation of erenumab, a CGRP receptor inhibitor for the prevention of migraine. Regul Toxicol Pharmacol 106:224–238

    Article  CAS  PubMed  Google Scholar 

  • Chapman RW, Skeans S, Lamca J et al (2005) Effect of histamine, albuterol and deep inspiration on airway and lung tissue mechanics in cynomolgus monkeys. Pulm Pharmacol Ther 18:243–249

    Article  CAS  PubMed  Google Scholar 

  • Charbit B, Samain E, Albaladejo et al (2004) QT interval prolongation after oxytocin bolus during surgical induced abortion. Clin Pharmacol Ther 76:359–364

    Article  CAS  PubMed  Google Scholar 

  • Chui RW, Fosdick A, Conner R et al (2009) Assessment of two external telemetry systems (PhysioJacket and JET) in beagle dogs with telemetry implants. J Pharmacol Toxicol Meth 60:58–68

    Article  CAS  Google Scholar 

  • Chui RW, Derakhchan K, Vargas HM (2011) Long-term assessment of non-human primate ECG using jacketed external telemetry (JET): evaluation of heart rate and QTc interval variation over 6 months of observation. J Pharmacol Toxicol Meth 64:e45

    Google Scholar 

  • Clayton AJ, Danson S, Jolly S et al (2004) Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer 91:639–643

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Cools F, Dhuyvetter D, Vanlommel A, Janssens S, Borghys H, Geys H, Gallacher DJ (2014) A translational assessment of preclinical versus clinical tools for the measurement of cardiac contractility: comparison of LV dP/dtmax with echocardiography in telemetry implanted beagle dogs. J Pharmacol Toxicol Methods 69(1):17–23

    Article  CAS  PubMed  Google Scholar 

  • Curran AK, Skeans S, Landers D et al (2008) Differential effects of dexamethasone on the proximal and distal lung response to antigen challenge in allergic cynomolgus monkeys. J Asthma 45:377–381

    Article  CAS  PubMed  Google Scholar 

  • de Hoon J, Van Hecken A, Vandermeulen C et al (2019) Phase 1, randomized, parallel-group, double-blind, placebo- controlled trial to evaluate the effects of erenumab (AMG 334) and concomitant sumatriptan on blood pressure in healthy volunteers. Cephalalgia 39:100–110

    Article  PubMed  Google Scholar 

  • de Zafra CLZ, Markgraf CG, Compton DR, Hudzik TJ (2018) Abuse liability assessment for biologic drugs – all molecules are not created equal. Regul Toxicol Pharmacol 92:165–172. https://doi.org/10.1016/j.yrtph.2017.11.019. Epub 2017 Dec 2

    Article  CAS  PubMed  Google Scholar 

  • Depre C, Antalik L, Starling A, Koren M, Eisele O, Lenz RA, Mikol DD (2018) A randomized, double-blind, placebo-controlled study to evaluate the effect of erenumab on exercise time during a treadmill test in patients with stable angina. Headache 58(5):715–723

    Article  PubMed  PubMed Central  Google Scholar 

  • Derakhchan K, Chui RW, Vargas HM (2011) Evaluation of cardiac conduction disturbances using jacketed external telemetry (JET) in conscious non-human primates. J Pharmacol Toxicol Methods 64(e46)

    Google Scholar 

  • Derakhchan K, Chui RW, Stevens D, Gu W, Vargas HM (2014) Detection of QTc interval prolongation using jacket telemetry in conscious non-human primates: comparison with implanted telemetry. Br J Pharmacol 171(2):509–522

    Article  CAS  PubMed  Google Scholar 

  • DiMasi JA, Feldman L, Seckler A et al (2010) Trends associated with new drug development: success rates for investigational drugs. Clin Pharm Ther 87:272–277

    Article  CAS  Google Scholar 

  • Dixit R, Iciek LA, McKeever K et al (2010) Challenges of general safety evaluations of biologics compared to small molecule pharmaceuticals in animal models. Expert Opin Drug Discov 5:79–94

    Article  CAS  PubMed  Google Scholar 

  • Drugs@FDA SANDOSTATIN® (1988), MYLOTARG® (2000), ADCETRIS® (2011) OMONTYS® (2012), SIGNIGOR® (2012), RAXIBACUMAB® (2012), and KADCYLA® (2013). http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?CFID=19379093&CFTOKEN=25eb8af4655376b-DCB09EA0-0293-9EC5-1C37C084658F1067

  • Ewart L, Aylott M, Deurinck M, Engwall M, Gallacher DJ, Geys H, …, Valentin JP (2014) The concordance between nonclinical and phase I clinical cardiovascular assessment from a cross-company data sharing initiative. Toxicol Sci 142(2):427–435

    Google Scholar 

  • FDA (2009) FDA statement on the voluntary withdrawal of RAPTIVA® from the U.S. Market. http://www.fda.gov/newsevents/newsroom/pressannouncements/2009/ucm149561.htm

  • FDA (2010a) Guidance for industry: assessment of abuse potential of drugs. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm198650.pdf

  • FDA (2010b) Gemtuzumab Ozogamicin (MYLOTARG®). http://www.fda.gov/aboutfda/centersoffices/officeofmedicalproductsandtobacco/cder/ucm216790.htm

  • FDA (2013a) Affymax and Takeda announce a nationwide voluntary recall of all lots of OMONTYS® (peginesatide) injection. http://www.fda.gov/safety/recalls/archiverecalls/2013/ucm340893.htm

  • FDA (2013b) Guidance for industry (2013) M3(R2) nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals – questions and answers (R2). Available at FDA.gov. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm292340.pdf

  • Frankel SR, Baeuerle (2013) Targeting T cells to tumor cells using bispecific antibodies. Curr Opin Chem Biol 17:385–392

    Article  CAS  PubMed  Google Scholar 

  • Freeman GB, Lin JC, Pons J et al (2012) 39-week toxicity and toxicokinetic study of ponezumab (PF-04360365) in cynomolgus monkeys with 12-week recovery period. J Alzheimers Dis 28:531–541

    Article  CAS  PubMed  Google Scholar 

  • Gabathuler R (2010) Approaches to transport therapeutic drugs across the blood brain barrier to treat brain diseases. Neurobiol Dis 37:48–57

    Article  CAS  PubMed  Google Scholar 

  • Gauvin DV, Baird TJ (2008) A functional observational battery in non-human primates for regulatory-required neurobehavioral assessments. J Pharmacol Toxicol Meth 58:88–93

    Article  CAS  Google Scholar 

  • Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Riesmeyer JS, Riddle MC, Rydén L, Xavier D, Atisso CM, Dyal L, Hall S, Rao-Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH, Temelkova-Kurktschiev T, REWIND Investigators (2019) Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 394(10193):121–130

    Article  CAS  PubMed  Google Scholar 

  • Giezen TJ, Mantel-Teeuwisse AK, Straus SM et al (2008) Safety-related regulatory actions for biological approved in the United States and the European Union. JAMA 300:1887–1896

    Article  CAS  PubMed  Google Scholar 

  • Guillon A, Leyre S, Remerand F et al (2010) Modification of Tp-e and QTc intervals during caesarean section under spinal anaesthesia. Anaesthesia 65:337–342

    Article  CAS  PubMed  Google Scholar 

  • Guth BD, Bass AS, Briscoe R et al (2009) Comparison of electrocardiographic analysis for risk of QT interval prolongation using safety pharmacology and toxicology studies. J Pharmacol Toxicol Meth 60:107–116

    Article  CAS  Google Scholar 

  • Hanton G, Eder V, Rochefort G, Bonnet P et al (2008) Echocardiography, a non-invasive method for the assessment of cardiac function and morphology in preclinical drug toxicology and safety pharmacology. Expert Opin Drug Metab Toxicol 4(6):681–696

    Article  CAS  PubMed  Google Scholar 

  • Harada N, Hoshiai K, Takahashi Y et al (2008) Preclinical safety pharmacology study of a novel protein-based cancer vaccine CHP-NY-ESO-1. Kobe J Med Sci 54:E23–E34

    PubMed  Google Scholar 

  • Hoffman W, Kallman MJ, Sgro M (2007) Respiratory safety pharmacology. Chapter 7. In: Sietsma WK, Schwen R (eds) Nonclinical drug safety assessment: practical considerations for successful registration. FDA News, Falls Church

    Google Scholar 

  • Hoymann HG (2012) Lung function measurements in rodents in safety pharmacology studies. Front Pharmacol 3:156

    Article  PubMed  PubMed Central  Google Scholar 

  • Hughes B (2009) 2008 FDA drug approval. Nature Rev Drug Disc 8:93–96

    Article  Google Scholar 

  • Hughes B (2010) 2009 FDA drug approval. Nature Rev Drug Disc 9:89–92

    Article  CAS  Google Scholar 

  • ICH M3(R2) (2009) Guidance on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. Available at ICH.org. Retrieved June 2013

  • ICH S6(R1) (2011) Preclinical safety evaluation of biotechnology-derived biopharmaceuticals. Available at ICH.org. Retrieved June 2013

  • ICH S7A (2000) Safety pharmacology studies for human biopharmaceuticals. Available at ICH.org. Retrieved June 2013

  • ICH S7B (2005) The nonclinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human biopharmaceuticals. Available at ICH.org. Retrieved June 2013

  • Iizuka H, Sasaki K, Odagiri N et al (2010) Measurement of respiratory function using whole-body plethysmography in unanesthetized and unrestrained non-humanprimates. J Toxicol Sci 35:863–870

    Article  CAS  PubMed  Google Scholar 

  • Ingram-Ross JL, Curran AK, Miyamoto M et al (2012) Cardiorespiratory safety evaluation in non-human primates. J Pharmacol Toxicol Meth 66:114–124

    Article  CAS  Google Scholar 

  • Jackson T, Kondic J, Seebeck J (2015) QT-prolonging effects of monoclonal antibody drugs in humans: a systematic review of two literature and a public adverse event database. Int J Clin Pharmacol Ther 53(9):705–711

    Article  CAS  PubMed  Google Scholar 

  • Kaiser RA, Erwin R, Tichenor SD et al (2010) Integration of cardiovascular safety pharmacology endpoints into general toxicology studies. J Pharmacol Toxicol Meth 62:e30

    Article  Google Scholar 

  • Kim TW, Kim KS, Seo JW, et al (2014) Antisense oligonucleotides on neurobehavior, respiratory and cardiovascular function and hERG channel current studies. J Pharmacol Toxicol Method (in press)

    Google Scholar 

  • Klein PM, Dybdal N (2003) Trastuzumab and cardiac dysfunction: update on preclinical studies. Semin Oncol 30:49–53

    Article  CAS  PubMed  Google Scholar 

  • Korte S, Fuchs A, Weinbauer GF et al (2007) Modified Irwin test as diagnostic tool to monitor neurobehavioral changes in monkeys. J Pharmacol Toxicol Meth 56:e47

    Article  Google Scholar 

  • Kurtz TW, Griffin KA, Bidani AK et al (2005) Recommendations for blood pressure measurement in humans and experimental animals. Hypertension 45:299–310

    Article  CAS  PubMed  Google Scholar 

  • Lawler JV, Endy TP, Hensley LE et al (2006) Cynomolgus macaque as an animal model for severe acute respiratory syndrome. PLoS Med 3:e149

    Article  PubMed  PubMed Central  Google Scholar 

  • Lebron JA, Wolf JJ, Kaplanski CV, Ledwith BJ (2005) Ensuring the quality, potency and safety of vaccines during preclinical development. Expert Rev Vaccines 4(6):855–866

    Article  CAS  PubMed  Google Scholar 

  • Lynch JJ III, Castagne V, Moser PC et al (2011) Comparison of methods for the assessment of locomotor activity in rodent safety pharmacology studies. J Pharmacol Toxicol Meth 64:74–80

    Article  CAS  Google Scholar 

  • Maki K (2020) Preclinical safety assessments of mRNA-targeting oligonucleotide therapeutics. Transl Regul Sci 2(3):90–93

    Google Scholar 

  • Marafino BJ, Pugsley MK (2003) Commercial development considerations for biotechnology-derived therapeutics. Cardiovascular Toxicol 3:5–12

    Article  CAS  Google Scholar 

  • Marlowe JL et al (2017) Recommendations of the oligonucleotide safety working Group’s formulated oligonucleotide subcommittee for the safety assessment of formulated oligonucleotide-based therapeutics. Nucleic Acid Therapeutics 27:83–196

    Article  Google Scholar 

  • McMahon C, Mitchell AZ, Klein JL et al (2010) Evaluation of blood pressure measurement using a miniature blood pressure transmitter with jacketed external telemetry in Cynomolgus monkeys. J Pharmacol Toxicol Meth 62:127–135

    Article  CAS  Google Scholar 

  • Miller KL, Lanthier M (2015 Feb) Regulatory watch: innovation in biologic new molecular entities: 1986–2014. Nat Rev Drug Discov 14(2):83

    Article  CAS  PubMed  Google Scholar 

  • Misra A, Ganesh Sand Shah SP (2003) Drug delivery to the central nervous system: a review. J Pharm Pharmaceut Sci 6:252–273

    CAS  Google Scholar 

  • Mitragotri S, Burke PA, Langer R (2014) Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies. Nat Rev Drug Discov 13(9):655–672

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Moscardo E, McPhie G, Fasdelli N et al (2010) An integrated cardiovascular and neurobehavioral functional assessment in the conscious telemetered Cynomolgus monkey. J Pharmacol Toxicol Meth 62:95–106

    Article  CAS  Google Scholar 

  • Mullard A (2011) 2010 FDA drug approval. Nature Rev Drug Disc 10:82–85

    Article  CAS  Google Scholar 

  • Mullard A (2012) 2011 FDA drug approval. Nature Rev Drug Disc 11:91–94

    Article  CAS  Google Scholar 

  • Mullard A (2013) 2012 FDA drug approval. Nature Rev Drug Disc 12:87–90

    Article  Google Scholar 

  • Murphy DJ (2002) Assessment of respiratory function in safety pharmacology. Fundam Clin Pharmacol 16:183–196

    Article  CAS  PubMed  Google Scholar 

  • Nalca A, Livingston VA, Garza NL et al (2010) Experimental infection of cynomolgus macaques (Macaca fascicularis) with aerosolized monkeypox virus. PLoS One 5:e12880

    Article  PubMed  PubMed Central  Google Scholar 

  • Niehoff M, Bartko T, Kremer J, Nichols J (2020) Evaluation of PhysioTel™ digital M11 cardiovascular telemetry implant in socially housed cynomolgus monkeys using etilefrine and moxifloxacin. J Pharmacol Toxicol Methods 105:106761

    Article  Google Scholar 

  • Ohlsson L, Haanes KA, Kronvall E et al (2019) Erenumab(AMG 334), a monoclonal antagonist antibody against the canonical CGRP receptor, does not impair vasodilatory or contractile responses to other vasoactive agents in human isolated cranial arteries. Cephalalgia 39:1745–1752

    Article  PubMed  Google Scholar 

  • Pardridge WM (2012) Drug transport across the blood-brain barrier. J Cerebral Blood Flow Metab 32:1959–1972

    Article  CAS  Google Scholar 

  • Pardridge WM, Boado RJ (2012) Reengineering biopharmaceuticals for targeted delivery across the blood–brain barrier. Meth Enzymol 503:269–292

    Article  CAS  Google Scholar 

  • Park E, Gintant GA, Bi D, Kozeli D, Pettit SD, Pierson JB, ..., Valentin JP (2018) Can non-clinical repolarization assays predict the results of clinical thorough QT studies? Results from a research consortium. Br J Pharmacol 175(4):606–617

    Google Scholar 

  • Pondé NF, Lambertini M, de Azambuja E (2016) Twenty years of anti-HER2 therapy-associated cardiotoxicity. ESMO open 1(4):e000073

    Article  PubMed  PubMed Central  Google Scholar 

  • Qu Y, Fang M, Gao B et al (2011) BeKm-1, a peptide inhibitor of hERG potassium currents, prolongs QTc interval in isolated rabbit hearts. J Pharmacol Exp Ther 337:2–8

    Article  CAS  PubMed  Google Scholar 

  • Qu Y, Fang M, Gao B et al (2014) Oxytocin does not directly alter cardiac repolarization in rabbit or human cardiac myocytes. Pharma Res Per 3(1) e00102. https://doi.org/10.1002/prp2.102

  • Redfern WS (2015) Inclusion of safety pharmacology endpoints in repeat-dose toxicity studies. Principles Safety Pharmacol 229:353–381

    Article  Google Scholar 

  • Redfern WS, Strang I, Storey S et al (2005) Spectrum of effects detected in the rat functional observational battery following oral administration of non-CNS targeted compounds. J Pharmacol Toxicol Meth 52:77–82

    Article  CAS  Google Scholar 

  • Redfern WS, Ewart LC, Lainee P et al (2013) Functional assessment in repeat-dose toxicity studies: the art of the possible. Toxicol Res. https://doi.org/10.1039/c3tx20093k

  • Rubio-Beltrán E, Labastida-Ramírez A, Haanes KA et al (2019) Characterisation of vasodilatory responses in the presence of the CGRP receptor antibody erenumab in human isolated arteries. Cephalalgia 39(14):1735–1744

    Article  PubMed  Google Scholar 

  • Santostefano MJ, Kirchner J, Vissinga C et al (2012) Off-target platelet activation in macaques unique to a therapeutic monoclonal antibody. Toxicol Pathol 40:899–917

    Article  CAS  PubMed  Google Scholar 

  • Sarazan RD, Mittelstadt S, Guth B et al (2011) Cardiovascular function in nonclinical drug safety assessment: current issues and opportunities. Int J Toxicol 30:272–286

    Article  PubMed  Google Scholar 

  • Schmelting B, Neihoff M, Egner B et al (2009) High-definition oscillometry: a novel technique for non-invasive blood pressure monitoring in the Cynomolgus monkey. J Med Primatol 38:293–301

    Article  CAS  PubMed  Google Scholar 

  • Schrieber SJ, Zhao H, Keegan P, Booth B, Rahman NA (2014) Evaluation of the potential for QT/QTc interval prolongation for therapeutic biotechnology products. J Clin Oncol 32(15_suppl):2600

    Article  Google Scholar 

  • Schubert D, Levin AA, Kornbrust D, Berman CL et al (2012) The oligonucleotide safety working group. Nucleic Acid Ther 22(4):211–213

    Article  CAS  PubMed  Google Scholar 

  • Scott LJ (2020) Dulaglutide: a review in type 2 diabetes. Drugs 80(2):197–208

    Article  CAS  PubMed  Google Scholar 

  • Shimamoto G, Gegg C, Boone T et al (2012) Peptibodies: a flexible alternative format to antibodies. MAbs 4(5):586–591

    Article  PubMed  PubMed Central  Google Scholar 

  • Skeans S, Lamca J, House A et al (2005) Airway closure after antigen challenge in cynomolgus monkeys: effect of the histamine H1 receptor antagonist, chlorpeniramine maleate. Int Arch Allergy Immunol 137:37–44

    Article  CAS  PubMed  Google Scholar 

  • Sun Y, Gruber M, Matsumoto M (2012) Overview of global regulatory toxicology requirements for vaccines and adjuvants. J Pharmacol Toxicol Meth 65:49–57

    Article  CAS  Google Scholar 

  • Sweeney MD, Zhao Z, Montagne A, Nelson AR, Zlokovic BV (2019) Blood-brain barrier: from physiology to disease and back. Physiol Rev 99(1):21–78

    Article  CAS  PubMed  Google Scholar 

  • Tong JTW, Harris PWR, Brimble MA, Kavianinia I (2021) An insight into FDA approved antibody-drug conjugates for cancer therapy. Molecules 26(19):5847

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Tse K, Sillito R, Keerie A, Collier R, Grant C, Karp NA, …, Redfern WS (2018) Pharmacological validation of individual animal locomotion, temperature and behavioural analysis in group-housed rats using a novel automated home cage analysis system: a comparison with the modified Irwin test. J Pharmacol Toxicol Methods 94:1–13

    Google Scholar 

  • Tsusaki H, Yonamine H, Tamai A, Shimomoto M, Iwao H, Nagata R, Kito G (2005) Evaluation of cardiac function in primates using real-time three-dimensional echocardiography as applications to safety assessment. J Pharmacol Toxicol Methods 52(1):182–187

    Article  CAS  PubMed  Google Scholar 

  • Uzun M, Yapar K, Uzlu E et al (2007) QT interval prolongation and decreased heart rates after intravenous bolus oxytocin injection in male and female conscious rabbits. Gen Physiol Biophys 26:168–172

    CAS  PubMed  Google Scholar 

  • Vachon C, Belanger MC, Burns PM (2014) Evaluation of oscillometric and Doppler ultrasonic devices for blood pressure measurements in anesthetized and conscious dogs. Res Vet Sci 97(1):111–117

    Article  PubMed  Google Scholar 

  • Vargas HM, Bass AS, Breidenbach A et al (2008) Scientific review and recommendations on preclinical cardiovascular safety evaluation of biologics. J Pharmacol Toxicol Meth 58:72–76

    Article  CAS  Google Scholar 

  • Vargas HM, Fang M, Gao BX et al (2013a) Oxytocin does not prolong repolarization in the isolated rabbit heart. Presented at the 13th annual meeting of safety pharmacology society, Rotterdam, September 16–19

    Google Scholar 

  • Vargas HM, Amouzadeh HR, Engwall MJ (2013b) Nonclinical strategy considerations for safety pharmacology: evaluation of biopharmaceuticals. Expert Opin Drug Saf 12(1):91–102

    Article  CAS  PubMed  Google Scholar 

  • Vargas HM, Rolf MG, Wisialowski TA, Achanzar W, Bahinski A, Bass A, …, Valentin JP (2021) Time for a fully integrated nonclinical–clinical risk assessment to streamline QT prolongation liability determinations: a pharma industry perspective. Clin Pharmacol Therap 109(2):310–318

    Google Scholar 

  • Wernick MB, Hopfner RM, Francey T et al (2012) Comparison of arterial blood pressure measurements and hypertension scores obtained by use of three indirect measurement devices in hospitalized dogs. J Am Vet Med Assoc 240:962–968

    Article  PubMed  Google Scholar 

  • WHO (2003) Guidelines on nonclinical evaluation of vaccines. Available at WHO.int

  • Wiśniowska B, Tylutki Z, Polak S (2020) An open-access dataset of thorough QT studies results. Data 5(1):10; https://doi.org/10.3390/data5010010

  • Yu YJ, Zhang Y, Kenrick M et al (2011) Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci Transl Med 3:1–8

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Translational Safety and Bioanalytical Sciences, Safety and Exploratory Pharmacology, Amgen Research, Thousand Oaks, CA, USA

    Michael J. Engwall, Weston Sutherland & Hugo M. Vargas

Authors
  1. Michael J. Engwall
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Weston Sutherland
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hugo M. Vargas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hugo M. Vargas .

Editor information

Editors and Affiliations

  1. CorDynamics, Dieburg, Hessen, Germany

    Franz J. Hock

  2. CorDynamics, Chicago, IL, USA

    Michael R. Gralinski

  3. Cytokinetics (United States), South San Francisco, CA, USA

    Michael K. Pugsley

Section Editor information

  1. self employes, Dieburg, Deutschland

    Franz J. Hock DSc

  2. CorDynamics, Chicago, IL, USA

    Michael R. Gralinski Ph.D.

Rights and permissions

Reprints and permissions

Copyright information

© 2022 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Engwall, M.J., Sutherland, W., Vargas, H.M. (2022). Safety Pharmacology Evaluation of Biopharmaceuticals. In: Hock, F.J., Gralinski, M.R., Pugsley, M.K. (eds) Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays. Springer, Cham. https://doi.org/10.1007/978-3-030-73317-9_18-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-73317-9_18-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-73317-9

  • Online ISBN: 978-3-030-73317-9

  • eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences

Publish with us

Policies and ethics

Search

Navigation